Atrasentan is an endothelin A receptor antagonist used in clinical research to reduce proteinuria and slow the progression of kidney disease, particularly in primary IgA nephropathy. In pharmaceutical… Read more





















![Chemical structure of Ethyl (2R,3R,4S)-4-(benzo[d][1,3]dioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)pyrrolidine-3-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F195708-08-8-Ethyl-2R3R4S-4-benzod13dioxol-5-yl-1-2-dibutylamino-2-oxoethyl-2-4-methoxyphenylpyrrolidine-3-carboxylate.png&w=3840&q=75)


Atrasentan is an endothelin A receptor antagonist used in clinical research to reduce proteinuria and slow the progression of kidney disease, particularly in primary IgA nephropathy. In pharmaceutical analysis, identifying and quantifying this compound requires a comprehensive set of analytical tools, including reference standards for the API, known impurities, and stereoisomers. Laboratories utilize these high-purity reference materials for rigorous impurity profiling and method validation, ensuring compliance with established quality control specifications. Additionally, stable isotope-labelled versions of Atrasentan are essential for supporting pharmacokinetic studies, where they serve as internal standards for mass spectrometry-based quantification. By providing access to these metabolites and related degradation products, researchers can effectively monitor compound stability and verify the accuracy of analytical methods throughout the drug development lifecycle.